Regulatory Approval

2 June 2009 ECO Animal Health Group plc ECO RECEIVES FURTHER APPROVAL FOR AIVLOSIN® ECO Animal Health Group plc is pleased to announce that its subsidiary ECO Animal Health Limited (ECO) has been granted registration approval from the European Commission to commence marketing its Aivlosin® 625 mg/g granules for oral solution for medicated drinking water for pigs. This marketing approval is the final step in the approval process and follows the positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency (EMEA) which we announced on 18 March 2009. ECO expects to commence marketing in early Autumn 2009. This new pan-European approval is in addition to the current European authorisations for the Aivlosin® product portfolio for use in pigs and poultry. This presentation of Aivlosin®, ECO's patented macrolide antibiotic, will be marketed for the treatment and prevention of ileitis (porcine proliferative enteropathy (PPE)), a market segment estimated to be worth in the region of US $30 million per annum at manufacturer level. Aivlosin® granules for oral solution dissolve readily in drinking water providing a simple solution for the accurate and simultaneous treatment of large numbers of pigs. Peter Lawrence, Chairman of ECO Animal Health Group plc, commented: "This is a very important approval and marks further progress in ECO's continuing development of Aivlosin® as a global veterinary product. It will significantly extend the sales and marketing reach of Aivlosin®" Contacts: ECO Animal Health Group plc Marc Loomes 020 8447 8899 Spiro Financial Anthony Spiro 020 8336 6196 Cenkos Securities plc Stephen Keys 020 7397 8926 (Nominated Adviser) Liz Bowman 020 7397 8928 ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.
UK 100

Latest directors dealings